Factors predicting survival in peripheral T-cell lymphoma in the USA

A population-based analysis of 8802 patients in the modern era

Adam M. Petrich, Irene B. Helenowski, Locke Johnson Bryan, Shaina A. Rozell, Robert Galamaga, Chadi Nabhan

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Summary: Current prognostic models for peripheral T-cell lymphoma (PTCL) have multiple limitations, and questions exist regarding applicability to current patients. We utilized the Surveillance Epidemiology and End Results (SEER)-18 database to evaluate factors affecting overall survival (OS) of PTCL in the modern era and identified 8802 patients between 2000-2010. Most subtypes of PTCL increased in incidence during the study period. In univariate analyses, age >55 years, black race, advanced stage, absence of extra-nodal disease, omission of radiation therapy (RT) and high-risk histology each predicted inferior OS (P < 0·0001). Multivariate analysis (MVA) demonstrated that hepatosplenic, enteropathy-associated and extra-nodal Natural Killer/T cell histologies, each had hazard ratios >1·5 (P ≤ 0·0001) for death. Further, age ≥55 years, black race and advanced stage maintained their significance in the MVA (P < 0·0001 each). Based on the significant factors, a prognostic model was constructed and subsequently validated in an independent cohort. The new model incorporated age, stage, histology and race, with an OS ranging from 9 months (highest risk group) to 120 months (lowest risk group). In summary, this is the largest study of PTCL patients in the modern era that provides risk stratification utilizing a new prognostic model that can be incorporated into future prospective clinical trials.

Original languageEnglish (US)
Pages (from-to)708-718
Number of pages11
JournalBritish Journal of Haematology
Volume168
Issue number5
DOIs
StatePublished - Mar 1 2015

Fingerprint

Peripheral T-Cell Lymphoma
Survival
Population
Histology
Epidemiology
Cohort Studies
Radiotherapy
Clinical Trials
Databases

Keywords

  • Histopathology
  • Prognostic factors
  • Radiotherapy
  • T-cell lymphoma

ASJC Scopus subject areas

  • Hematology

Cite this

Factors predicting survival in peripheral T-cell lymphoma in the USA : A population-based analysis of 8802 patients in the modern era. / Petrich, Adam M.; Helenowski, Irene B.; Bryan, Locke Johnson; Rozell, Shaina A.; Galamaga, Robert; Nabhan, Chadi.

In: British Journal of Haematology, Vol. 168, No. 5, 01.03.2015, p. 708-718.

Research output: Contribution to journalArticle

Petrich, Adam M. ; Helenowski, Irene B. ; Bryan, Locke Johnson ; Rozell, Shaina A. ; Galamaga, Robert ; Nabhan, Chadi. / Factors predicting survival in peripheral T-cell lymphoma in the USA : A population-based analysis of 8802 patients in the modern era. In: British Journal of Haematology. 2015 ; Vol. 168, No. 5. pp. 708-718.
@article{ef7df614a5634dfe9959aa64ae4f3c9a,
title = "Factors predicting survival in peripheral T-cell lymphoma in the USA: A population-based analysis of 8802 patients in the modern era",
abstract = "Summary: Current prognostic models for peripheral T-cell lymphoma (PTCL) have multiple limitations, and questions exist regarding applicability to current patients. We utilized the Surveillance Epidemiology and End Results (SEER)-18 database to evaluate factors affecting overall survival (OS) of PTCL in the modern era and identified 8802 patients between 2000-2010. Most subtypes of PTCL increased in incidence during the study period. In univariate analyses, age >55 years, black race, advanced stage, absence of extra-nodal disease, omission of radiation therapy (RT) and high-risk histology each predicted inferior OS (P < 0·0001). Multivariate analysis (MVA) demonstrated that hepatosplenic, enteropathy-associated and extra-nodal Natural Killer/T cell histologies, each had hazard ratios >1·5 (P ≤ 0·0001) for death. Further, age ≥55 years, black race and advanced stage maintained their significance in the MVA (P < 0·0001 each). Based on the significant factors, a prognostic model was constructed and subsequently validated in an independent cohort. The new model incorporated age, stage, histology and race, with an OS ranging from 9 months (highest risk group) to 120 months (lowest risk group). In summary, this is the largest study of PTCL patients in the modern era that provides risk stratification utilizing a new prognostic model that can be incorporated into future prospective clinical trials.",
keywords = "Histopathology, Prognostic factors, Radiotherapy, T-cell lymphoma",
author = "Petrich, {Adam M.} and Helenowski, {Irene B.} and Bryan, {Locke Johnson} and Rozell, {Shaina A.} and Robert Galamaga and Chadi Nabhan",
year = "2015",
month = "3",
day = "1",
doi = "10.1111/bjh.13202",
language = "English (US)",
volume = "168",
pages = "708--718",
journal = "British Journal of Haematology",
issn = "0007-1048",
publisher = "Wiley-Blackwell",
number = "5",

}

TY - JOUR

T1 - Factors predicting survival in peripheral T-cell lymphoma in the USA

T2 - A population-based analysis of 8802 patients in the modern era

AU - Petrich, Adam M.

AU - Helenowski, Irene B.

AU - Bryan, Locke Johnson

AU - Rozell, Shaina A.

AU - Galamaga, Robert

AU - Nabhan, Chadi

PY - 2015/3/1

Y1 - 2015/3/1

N2 - Summary: Current prognostic models for peripheral T-cell lymphoma (PTCL) have multiple limitations, and questions exist regarding applicability to current patients. We utilized the Surveillance Epidemiology and End Results (SEER)-18 database to evaluate factors affecting overall survival (OS) of PTCL in the modern era and identified 8802 patients between 2000-2010. Most subtypes of PTCL increased in incidence during the study period. In univariate analyses, age >55 years, black race, advanced stage, absence of extra-nodal disease, omission of radiation therapy (RT) and high-risk histology each predicted inferior OS (P < 0·0001). Multivariate analysis (MVA) demonstrated that hepatosplenic, enteropathy-associated and extra-nodal Natural Killer/T cell histologies, each had hazard ratios >1·5 (P ≤ 0·0001) for death. Further, age ≥55 years, black race and advanced stage maintained their significance in the MVA (P < 0·0001 each). Based on the significant factors, a prognostic model was constructed and subsequently validated in an independent cohort. The new model incorporated age, stage, histology and race, with an OS ranging from 9 months (highest risk group) to 120 months (lowest risk group). In summary, this is the largest study of PTCL patients in the modern era that provides risk stratification utilizing a new prognostic model that can be incorporated into future prospective clinical trials.

AB - Summary: Current prognostic models for peripheral T-cell lymphoma (PTCL) have multiple limitations, and questions exist regarding applicability to current patients. We utilized the Surveillance Epidemiology and End Results (SEER)-18 database to evaluate factors affecting overall survival (OS) of PTCL in the modern era and identified 8802 patients between 2000-2010. Most subtypes of PTCL increased in incidence during the study period. In univariate analyses, age >55 years, black race, advanced stage, absence of extra-nodal disease, omission of radiation therapy (RT) and high-risk histology each predicted inferior OS (P < 0·0001). Multivariate analysis (MVA) demonstrated that hepatosplenic, enteropathy-associated and extra-nodal Natural Killer/T cell histologies, each had hazard ratios >1·5 (P ≤ 0·0001) for death. Further, age ≥55 years, black race and advanced stage maintained their significance in the MVA (P < 0·0001 each). Based on the significant factors, a prognostic model was constructed and subsequently validated in an independent cohort. The new model incorporated age, stage, histology and race, with an OS ranging from 9 months (highest risk group) to 120 months (lowest risk group). In summary, this is the largest study of PTCL patients in the modern era that provides risk stratification utilizing a new prognostic model that can be incorporated into future prospective clinical trials.

KW - Histopathology

KW - Prognostic factors

KW - Radiotherapy

KW - T-cell lymphoma

UR - http://www.scopus.com/inward/record.url?scp=84922779526&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84922779526&partnerID=8YFLogxK

U2 - 10.1111/bjh.13202

DO - 10.1111/bjh.13202

M3 - Article

VL - 168

SP - 708

EP - 718

JO - British Journal of Haematology

JF - British Journal of Haematology

SN - 0007-1048

IS - 5

ER -